PubRank

Jan Cools

Author PubWeight™ 111.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 17.41
2 The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012 9.89
3 Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005 3.90
4 Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007 3.48
5 Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet 2012 2.64
6 Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003 2.61
7 Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007 2.55
8 Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006 2.23
9 The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005 2.14
10 The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2003 2.09
11 The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008 1.95
12 Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010 1.79
13 Atonal homolog 1 is a tumor suppressor gene. PLoS Biol 2009 1.76
14 In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 2008 1.69
15 Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet 2010 1.68
16 CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003 1.63
17 Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica 2005 1.43
18 Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci U S A 2006 1.40
19 Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res 2006 1.34
20 The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007 1.28
21 Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005 1.27
22 Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011 1.27
23 Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007 1.18
24 MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context. Haematologica 2010 1.16
25 Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008 1.16
26 Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007 1.15
27 ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 2010 1.14
28 Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 2004 1.13
29 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006 1.10
30 The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica 2011 1.10
31 JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 2011 1.09
32 High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012 1.08
33 Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 2008 1.07
34 Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology 2006 1.03
35 Novel approaches to therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007 1.01
36 Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 2012 1.01
37 Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood 2008 1.01
38 Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. Mol Cell 2008 0.98
39 The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica 2009 0.96
40 Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008 0.96
41 PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 2011 0.94
42 Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. Blood 2007 0.92
43 Genetic and epigenetic studies offer new therapeutic options for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 2012 0.90
44 Cancer: Mutations close in on gene regulation. Nature 2013 0.90
45 Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen. Haematologica 2009 0.89
46 Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma. Haematologica 2011 0.87
47 A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene. Genes Chromosomes Cancer 2003 0.87
48 Cellular transformation of NIH3T3 fibroblasts by CIZ/NMP4 fusions. J Cell Biochem 2005 0.86
49 G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood 2014 0.86
50 Improvements in the survival of children and adolescents with acute lymphoblastic leukemia. Haematologica 2012 0.86
51 JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines. Haematologica 2009 0.85
52 Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer 2013 0.82
53 EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. PLoS Med 2005 0.82
54 The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012 0.80
55 FLT1 kinase is a mediator of radioresistance and survival in head and neck squamous cell carcinoma. Acta Oncol 2013 0.79
56 When splicing turns bad. Haematologica 2012 0.78
57 FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis. Hematol J 2004 0.78
58 Chromosomal aberrations and fusion genes in myeloid malignancies. Expert Rev Hematol 2012 0.78
59 BMI1, the polycomb-group gene, is recurrently targeted by genomic rearrangements in progressive B-cell leukemia/lymphoma. Genes Chromosomes Cancer 2013 0.78
60 Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. Expert Rev Anticancer Ther 2009 0.78
61 DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia. Haematologica 2014 0.78
62 JAK3 specific kinase inhibitors: when specificity is not enough. Chem Biol 2011 0.78
63 Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL. Blood 2012 0.78
64 Using the hemoglobin switch for the treatment of sickle cell disease. Haematologica 2012 0.77
65 The hypereosinophilic syndrome: idiopathic or not, that is the question. Haematologica 2005 0.77
66 TV6 and PDGFRB: a license to fuse. Haematologica 2007 0.77
67 Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13). Haematologica 2006 0.76
68 Primetime for chemotherapy in acute myeloid leukemia. Haematologica 2012 0.76
69 Resolutions for the New Year. Haematologica 2016 0.75
70 Development of a siRNA and shRNA screening system based on a kinase fusion protein. RNA 2012 0.75
71 A fly's view of the hematopoietic niche. Haematologica 2012 0.75
72 New opportunities and new problems for acute myeloid leukemia treatment. Haematologica 2012 0.75
73 Detection of clonal blood cells with specific chromosomal abnormalities in the general population. Haematologica 2012 0.75
74 New flow cytometry in hematologic malignancies. Haematologica 2009 0.75
75 Identification of novel FLT3 kinase inhibitors. Eur J Med Chem 2013 0.75